Transcatheter arterial chemoembolization and radiation therapy for treatment-naïve patients with locally advanced hepatocellular carcinomaopen access
- Authors
- Kim S.W.[Kim S.W.]; Oh D.[Oh D.]; Park H.C.[Park H.C.]; Lim D.H.[Lim D.H.]; Shin S.W.[Shin S.W.]; Cho S.K.[Cho S.K.]; Gwak G.-Y.[Gwak G.-Y.]; Choi M.S.[Choi M.S.]; Paik Y.H.[Paik Y.H.]; Paik S.W.[Paik S.W.]
- Issue Date
- 2014
- Keywords
- Hepatocellular carcinoma; Radiotherapy; Transcatheter arterial chemoembolization
- Citation
- Radiation Oncology Journal, v.32, no.1, pp.14 - 22
- Journal Title
- Radiation Oncology Journal
- Volume
- 32
- Number
- 1
- Start Page
- 14
- End Page
- 22
- URI
- https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/58042
- DOI
- 10.3857/roj.2014.32.1.14
- ISSN
- 2234-3164
- Abstract
- Purpose To evaluate the safety and efficacy of transcatheter arterial chemoembolization (TACE) followed by radiotherapy (RT) in treatment-naïve patients with locally advanced hepatocellular carcinoma (HCC). Materials and Methods Eligibility criteria were as follows: newly diagnosed with HCC, the Barcelona Clinic Liver Cancer stage C, Child-Pugh class A or B, and no prior treatment for HCC. Patients with extrahepatic spread were excluded. A total of 59 patients were retrospectively enrolled. All patients were treated with TACE followed by RT. The time interval between TACE and RT was 2 weeks as per protocol. A median RT dose was 47.25 Gy10 as the biologically effective dose using the α/β = 10 (range, 39 to 65.25 Gy10). Results At 1 month, complete response was obtained in 3 patients (5%), partial response in 27 patients (46%), stable disease in 13 patients (22%), and progressive disease in 16 patients (27%). The actuarial one- and two-year OS rates were 60.1% and 47.2%, respectively. The median OS was 17 months (95% confidence interval, 5.6 to 28.4 months). The median time to progression was 4 months (range, 1 to 35 months). Grade 3 or greater liver enzyme elevation occurred in only two patients (3%) after RT. Grade 3 gastroduodenal toxicity developed in two patients (3%). Conclusion The combination treatment of TACE followed by RT with two-week interval was safe and it showed favorable outcomes in treatment-naïve patients with locally advanced HCC. A prospective randomized trial is needed to validate these results. © 2014. The Korean Society for Radiation Oncology.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.